| Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR X Ma, L Long, S Moon, BJS Adamson, SS Baxi Medrxiv, 2020.03. 16.20037143, 2020 | 266 | 2020 |
| MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer ME Roberts, SA Jackson, LR Susswein, N Zeinomar, X Ma, ML Marshall, ... Genetics in Medicine 20 (10), 1167-1174, 2018 | 148 | 2018 |
| Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk MB Terry, MB Daly, KA Phillips, X Ma, N Zeinomar, N Leoce, GS Dite, ... JNCI: Journal of the National Cancer Institute 111 (3), 331-334, 2019 | 40 | 2019 |
| Characterization of a real-world response variable and comparison with RECIST-based response rates from clinical trials in advanced NSCLC X Ma, L Bellomo, K Magee, CS Bennette, O Tymejczyk, M Samant, ... Advances in therapy 38, 1843-1859, 2021 | 25 | 2021 |
| Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC) X Ma, NC Nussbaum, K Magee, AB Bourla, M Tucker, L Bellomo, ... Annals of Oncology 30, v651, 2019 | 19 | 2019 |
| Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. medRxiv. 2020: 2020.03. 16.20037143 X Ma, L Long, S Moon, BJS Adamson, SS Baxi Preprint, not peer-reviewed, 2022 | 15 | 2022 |
| Differential frequency in imaging‐based outcome measurement: Bias in real‐world oncology comparative‐effectiveness studies BJS Adamson, X Ma, SD Griffith, EM Sweeney, S Sarkar, AB Bourla Pharmacoepidemiology and Drug Safety 31 (1), 46-54, 2022 | 8 | 2022 |
| The steroid metabolome and breast cancer risk in women with a family history of breast cancer: the novel role of adrenal androgens and glucocorticoids LC Houghton, RE Howland, Y Wei, X Ma, RD Kehm, WK Chung, ... Cancer Epidemiology, Biomarkers & Prevention 30 (1), 89-96, 2021 | 8 | 2021 |
| Evaluating the impact of oncology care model reporting requirements on biomarker testing and treatment EH Castellanos, A Orlando, X Ma, RB Parikh, G O’Connell, NJ Meropol, ... JCO Oncology Practice 16 (10), e1216-e1221, 2020 | 8 | 2020 |
| Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. medRxiv; 2020; 03.16. 20037143 X Ma, L Long, S Moon, BJS Adamson, SS Baxi | 7 | 2020 |
| Comparison of population characteristics in real-world clinical oncology databases in the US: flatiron health, SEER, and NPCR. MedRvix https://www. medrxiv. org/content/10.1101 … X Ma, L Long, S Moon, BJS Adamson, SS Baxi Accessed 24th Nov, 2021 | 6 | 2021 |
| Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR [preprint published online May 30, 2020] X Ma, L Long, S Moon, BJS Adamson, SS Baxi medRxiv, 0 | 6 | |
| Concordance of clinician-documented and imaging response in patients with stage IV non–small cell lung cancer treated with first-line therapy X Ma, L Bellomo, I Hooley, T Williams, M Samant, K Tan, B Segal, ... JAMA Network Open 5 (5), e229655-e229655, 2022 | 5 | 2022 |
| Using time-varying quantile regression approaches to model the influence of prenatal and infant exposures on childhood growth Y Wei, X Ma, X Liu, MB Terry Biostatistics & Epidemiology 1 (1), 133-147, 2017 | 3 | 2017 |
| Abstract C082: Prenatal exposure to polycyclic aromatic hydrocarbons and altered DNA methylation in breast cancer-related genes N Zeinomar, HC Wu, X Ma, JB Herbstman, FP Perera, RL Miller, MB Terry Cancer Epidemiology, Biomarkers & Prevention 29 (6_Supplement_1), C082-C082, 2020 | 1 | 2020 |
| Impact of Oncology Care Model (OCM) reporting requirements on quality of care. E Castellanos, A Orlando, J Hamrick, X Ma, G O'Connell, NJ Meropol, ... Journal of Clinical Oncology 37 (15_suppl), 6620-6620, 2019 | 1 | 2019 |
| Impacts of the COVID-19 pandemic on assessment of progression and surveillance bias in advanced non-small cell lung cancer LE Johns, YH Zhao, XR Ma, RA Miksad, SD Griffith Pharmacoepidemiology and Drug Safety, 450-450, 2022 | | 2022 |
| Cover Image, Volume 31, Issue 1 BJS Adamson, X Ma, SD Griffith, EM Sweeney, S Sarkar, AB Bourla Pharmacoepidemiology and Drug Safety 31 (1), i-i, 2022 | | 2022 |
| Abstract PD6-05: Withdrawn RD Kehm, KA Phillips, MB Daly, IL Andrulis, Y Liao, X Ma, N Zeinomar, ... Cancer Research 79 (4_Supplement), PD6-05-PD6-05, 2019 | | 2019 |
| Abstract P6-09-01: Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk using a prospective family study cohort (ProF-SC) MB Terry, KA Phillips, MB Daly, IL Andrulis, Y Liao, X Ma, N Zeinomar, ... Cancer Research 78 (4_Supplement), P6-09-01-P6-09-01, 2018 | | 2018 |
